Skip to content

Study · Ex vivo tissue · 2000

6 results

Interaction of the novel GH secretagogue hexarelin with GHRH in regulating the secretion of GH by cultured human pituitary somatotrophinomas in vitro.

Liu Q, Lei T, Liu K, Lin W, Adams EF

Journal of Tongji Medical University = Tong ji yi ke da xue xue bao1 Jan 2000

PMID12845719 (opens in a new tab)DOI10.1007/bf02887044 (opens in a new tab)PepBankPUB-12845719
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueEfficacy outcome

    In cultured human pituitary somatotrophinomas, hexarelin strongly stimulated GH secretion.

    In plain wordsIn lab-grown human pituitary tumour cells, hexarelin strongly increased growth hormone release.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH secretion
    Study

    humann: not reported in source

    cultured human pituitary somatotrophinomas
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 nmol/LAs given in this study (human).

    Source sentences

    Summary
    Hexarelin (20 nmol/L) strongly stimulated GH secretion
    1 context sentence
    Summary · context
    The effects of the novel GH-releasing hexapeptide, Hexarelin, on the secretion of GH in cultured human pituitary somatotrophinomas was further investigated.
  2. 02LabEx vivo tissueMechanism

    In cultured human pituitary somatotrophinomas, hexarelin alone had no effect on cAMP levels.

    In plain wordsIn lab-grown human pituitary tumour cells, hexarelin alone did not change cAMP levels.

    Peptide
    Hexarelin
    Outcome
    No significant changecAMP levels
    Study

    humann: not reported in source

    cultured human pituitary somatotrophinomas
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    When added alone to somatotrophinoma cell cultures, Hexarelin had no effect on cAMP levels
    1 context sentence
    Summary · context
    The effects of the novel GH-releasing hexapeptide, Hexarelin, on the secretion of GH in cultured human pituitary somatotrophinomas was further investigated.
  3. 03LabEx vivo tissueMechanism

    In cultured human pituitary somatotrophinomas, hexarelin potentiated the stimulatory effects of GHRH.

    In plain wordsIn lab-grown human pituitary tumour cells, hexarelin strengthened the effects of GHRH.

    Peptide
    Hexarelin
    Outcome
    IncreasePotentiation of GHRH stimulatory effects
    Study

    humann: not reported in source

    cultured human pituitary somatotrophinomas
    Comparator
    GHRH alone
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but it potentiated the stimulatory effects of GHRH.
    1 context sentence
    Summary · context
    The effects of the novel GH-releasing hexapeptide, Hexarelin, on the secretion of GH in cultured human pituitary somatotrophinomas was further investigated.

Studies that did not test the peptide alone3

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

  1. 04LabNot a test of Hexarelin aloneEx vivo tissueMechanism

    In cultured human pituitary somatotrophinomas, phloretin reduced the GH secretion stimulated by hexarelin.

    In plain wordsIn lab-grown human pituitary tumour cells, phloretin lowered the growth hormone release caused by hexarelin.

    Peptide
    Hexarelin
    Outcome
    DecreaseHexarelin-stimulated GH secretion with phloretin
    Study

    humann: not reported in source

    cultured human pituitary somatotrophinomas
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    Hexarelin (20 nmol/L) strongly stimulated GH secretion, which could be reduced by phloretin, but not by RP-cAMPS, an inhibitor of protein kinase A (PKA).
    1 context sentence
    Summary · context
    The effects of the novel GH-releasing hexapeptide, Hexarelin, on the secretion of GH in cultured human pituitary somatotrophinomas was further investigated.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  2. 05LabNot a test of Hexarelin aloneEx vivo tissueMechanism

    In cultured human pituitary somatotrophinomas, the protein kinase A inhibitor RP-cAMPS did not reduce hexarelin-stimulated GH secretion.

    In plain wordsIn lab-grown human pituitary tumour cells, a protein kinase A blocker did not lower the growth hormone release caused by hexarelin.

    Peptide
    Hexarelin
    Outcome
    No significant changeHexarelin-stimulated GH secretion with RP-cAMPS
    Study

    humann: not reported in source

    cultured human pituitary somatotrophinomas
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    Hexarelin (20 nmol/L) strongly stimulated GH secretion, which could be reduced by phloretin, but not by RP-cAMPS, an inhibitor of protein kinase A (PKA).
    1 context sentence
    Summary · context
    The effects of the novel GH-releasing hexapeptide, Hexarelin, on the secretion of GH in cultured human pituitary somatotrophinomas was further investigated.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  3. 06LabNot a test of Hexarelin aloneEx vivo tissueMechanism

    In cultured human pituitary somatotrophinomas, a GHRH antagonist failed to block the effects of hexarelin.

    In plain wordsIn lab-grown human pituitary tumour cells, a GHRH blocker did not stop the effects of hexarelin.

    Peptide
    Hexarelin
    Outcome
    No significant changeHexarelin-stimulated GH secretion with GHRH antagonist
    Study

    humann: not reported in source

    cultured human pituitary somatotrophinomas
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    (Ac-Tyr1,D-Arg2)-GRF(1-29)-NH2 failed to block the effects of Hexarelin
    1 context sentence
    Summary · context
    The effects of the novel GH-releasing hexapeptide, Hexarelin, on the secretion of GH in cultured human pituitary somatotrophinomas was further investigated.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Versions 2 to 3

    13 Oct 2026, 16:31 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:13 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.